Taxotere Eye Injury Lawsuits: What MDL 3023 Shows

Taxotere is the brand name of docetaxel, a chemotherapy drug that the FDA first approved in 1996. Federal lawsuits alleging that docetaxel caused permanent tear duct injuries and excessive tearing are consolidated as MDL No. 3023, In re: Taxotere (Docetaxel) Eye Injury Products Liability Litigation, in the Eastern District of Louisiana before Judge Jane Triche Milazzo. The Judicial Panel on Multidistrict Litigation reported 138 actions pending of 433 filed as of October 1, 2026. In December 2022 the court allowed strict-liability failure-to-warn and negligence claims to proceed at the pleading stage and dismissed the fraud-based counts. No court has found that the drug caused any plaintiff’s eye injury, and the documents reviewed here record no trial verdict and no approved settlement.

What is alleged, and what the court has decided

The Panel’s transfer order, filed February 1, 2022, describes the actions as sharing “factual questions arising from allegations that the chemotherapy drug Taxotere (docetaxel) can cause users to suffer permanent eye damage, and that defendants failed to warn patients.” It adds: “Plaintiffs in these actions each allege that they developed excessive tearing (epiphora) as a result of permanent injuries to their tear ducts after chemotherapy treatment with Taxotere.”

Those are the plaintiffs’ allegations. They are not findings. The order records that the Panel centralized the actions for coordinated pretrial proceedings because they involved common questions of fact, and it assigned them to Judge Milazzo in a district where a separate Taxotere proceeding, MDL No. 2740, was already pending. The Panel noted that the injury in MDL No. 2740, permanent hair loss, is different from the eye injury alleged in MDL No. 3023.

The court addressed the merits of the pleadings on December 5, 2022. In two orders issued the same day, Judge Milazzo ruled on motions to dismiss filed by the Sanofi defendants and by a group described as the 505(b)(2) defendants. Each motion was “DENIED IN PART and GRANTED IN PART.” The court denied dismissal of Count I, strict products liability for failure to warn, and Count II, negligence. It granted dismissal of Count III, negligent misrepresentation, Count IV, fraudulent misrepresentation, and Count V, fraudulent concealment, because those claims did not meet the particularity requirement of Federal Rule of Civil Procedure 9(b). The court gave the plaintiffs twenty days to seek leave to amend those counts.

The ruling was a decision about the sufficiency of the complaint, not about whether the drug causes eye injuries. The court wrote that the fraud-based allegations “merely restate failure to warn claims and affix words like ’negligently,’ ‘fraudulently,’ and ‘intentionally’” to the legal elements. That is a pleading defect. It is not a finding that the warnings were adequate or that the drug was safe.

What the FDA label says about the eye

Docetaxel is a taxane, a class of chemotherapy drugs that interferes with microtubules and blocks cell division, according to the National Cancer Institute. The label reviewed here is indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of the head and neck.

Two parts of the label are relevant to the litigation, and they concern different eye conditions. Section 5.10, headed Eye Disorders, addresses cystoid macular edema. It states that the condition “has been reported in patients treated with docetaxel,” that patients with impaired vision should receive a prompt ophthalmologic examination, and that treatment should be discontinued if the condition is diagnosed.

The lacrimal language appears elsewhere. Section 6.2, Postmarketing Experience, lists among ophthalmologic reactions: “conjunctivitis, lacrimation or lacrimation with or without conjunctivitis, cystoid macular edema (CME). Excessive tearing which may be attributable to lacrimal duct obstruction.” The patient counseling section likewise tells patients that “vision disturbances and excessive tearing are associated with docetaxel administration” and instructs them to report any vision changes.

The label does not use the words stenosis, epiphora, tear duct or lacrimal specialist. Those terms appear in the plaintiffs’ allegations as the December 2022 order recites them, not in the prescribing information. The label’s revised date is January 2023. A warning or an adverse-reaction listing is a regulatory statement about reports; it is not a finding that the drug caused a particular patient’s condition.

What is established vs. what is alleged

Established by the documents reviewed here: the drug’s approved indications and its labeling language about eye disorders; the existence of MDL No. 3023, its court, its judge and its docket number; the Panel’s transfer order and its description of the claims; the court’s December 5, 2022 rulings on the motions to dismiss; and the case counts reported by the Panel as of October 1, 2026.

Alleged, and not decided: that docetaxel causes permanent injuries to the tear ducts; that those injuries produce excessive tearing or epiphora; that the injuries can occur rapidly or become irreversible; that patients should have been referred to a lacrimal specialist during chemotherapy; and that the defendants’ warnings were inadequate. The plaintiffs also alleged that the defendants concealed the rapid onset of stenosis, its potentially irreversible nature, the need for prompt referral and the possibility of prevention with timely intervention. The court quoted those allegations when it dismissed the fraud counts on pleading grounds.

Where the claims stand procedurally

MDL No. 3023 is a consolidated pretrial proceeding, not a class action. Each plaintiff keeps an individual claim. The Panel’s transfer order recorded that the litigation began with six actions in four districts and that the parties represented at oral argument that thirteen actions were then pending. The Panel’s statistics report dated October 1, 2026 lists 433 actions filed in total and 138 still pending. The report does not say how the other actions were resolved, whether by dismissal, settlement, remand or another disposition.

The court’s public page for the MDL lists no development after July 20, 2023, when the court entered an order resetting a status conference to September 12, 2023. Earlier entries on that page include a Science Day held on February 13, 2023, Pretrial Order No. 4 setting plaintiff and defendant fact sheets, and the December 5, 2022 dismissal orders. The page is a court publication, but it is not the docket itself. A current docket check through PACER would be needed to establish what has happened since.

Key dates

• 1996: the FDA grants initial approval to docetaxel (prescribing information).
• February 1, 2022: the Panel transfers the eye injury actions to the Eastern District of Louisiana and assigns them to Judge Jane Triche Milazzo (transfer order).
• December 5, 2022: the court denies dismissal of the failure-to-warn and negligence counts and dismisses the three fraud-based counts with twenty days to seek leave to amend (orders and reasons).
• January 2023: the revision date shown on the prescribing information reviewed here (label).
• July 20, 2023: the court resets a status conference to September 12, 2023, the last entry listed on its public MDL page (court page).
• October 1, 2026: the Panel reports 138 actions pending of 433 filed in MDL No. 3023 (statistics report).

What this does not establish

Nothing in the documents reviewed here shows a court finding that docetaxel caused any individual’s eye injury. The MDL is a pretrial consolidation, and the December 2022 orders decided only whether the complaint stated claims, not whether the claims are true. A denial of a motion to dismiss means the case may proceed; it is not a finding of liability.

The label language has similar limits. The FDA’s listing of excessive tearing that may be attributable to lacrimal duct obstruction records reported reactions. The label itself does not establish causation in any individual case, and it does not use the word stenosis. The agency has not, in the documents reviewed, issued a conclusion that docetaxel causes permanent tear duct injuries.

The documents reviewed also record no trial verdict, no announced settlement and no court-approved settlement in MDL No. 3023. Their absence from these documents is not proof that no event has occurred. It means the record reviewed here does not establish one.

Frequently asked questions

Is there a Taxotere eye injury settlement?

No settlement appears in the documents reviewed here. MDL No. 3023 is a consolidated pretrial proceeding, and the Panel’s October 2026 report records pending cases, not a resolution. A settlement would require its own court filings and, if it resolved claims on a class-wide basis, a fairness hearing and approval.

What injury do the plaintiffs allege?

The Panel’s transfer order states that each plaintiff alleges excessive tearing, or epiphora, resulting from permanent injuries to the tear ducts after chemotherapy with Taxotere. The plaintiffs also allege that the defendants failed to warn patients about that risk. Those are allegations, not established facts.

Did a court rule that Taxotere causes eye damage?

No. The December 5, 2022 orders allowed failure-to-warn and negligence claims to proceed past a motion to dismiss and dismissed the fraud-based counts on pleading grounds. No document reviewed here records a trial or a causation ruling.

Is this the same as the Taxotere hair loss litigation?

No. The Panel’s transfer order identifies MDL No. 2740 as a separate Taxotere proceeding, also before Judge Milazzo, concerning permanent hair loss. The order states that the injury alleged in MDL No. 3023 is different.

Does the FDA label warn about tear duct injury?

The label lists excessive tearing that may be attributable to lacrimal duct obstruction in its postmarketing adverse reactions section. Its dedicated Eye Disorders warning, section 5.10, addresses cystoid macular edema. The label reviewed here does not use the terms stenosis, epiphora or tear duct. For background on how consolidated proceedings differ from class actions, see the guide on MDLs and class actions, alongside the pharmaceutical lawsuits hub and the Elmiron vision injury litigation.

Sources

1. U.S. Judicial Panel on Multidistrict Litigation: “MDL Statistics Report: Distribution of Pending MDL Dockets by District, October 1, 2026” (link, accessed 2026-10-17)
2. U.S. Judicial Panel on Multidistrict Litigation: “Transfer Order, In re: Taxotere (Docetaxel) Eye Injury Products Liability Litigation, MDL No. 3023 (February 1, 2022)” (link, accessed 2026-10-17)
3. U.S. District Court for the Eastern District of Louisiana: “Order and Reasons on Sanofi’s Motion to Dismiss, In re: Taxotere (Docetaxel) Eye Injury Products Liability Litigation, No. 22-3023 (E.D. La. December 5, 2022)” (link, accessed 2026-10-17)
4. U.S. District Court for the Eastern District of Louisiana: “Order and Reasons on the 505(b)(2) Defendants’ Motion to Dismiss, In re: Taxotere (Docetaxel) Eye Injury Products Liability Litigation, No. 22-3023 (E.D. La. December 5, 2022)” (link, accessed 2026-10-17)
5. U.S. District Court for the Eastern District of Louisiana: “Taxotere (Docetaxel) Eye Injury Products Liability Litigation, MDL 3023” (link, accessed 2026-10-17)
6. National Library of Medicine, DailyMed: “Docetaxel injection, Prescribing Information (label revised January 2023)” (link, accessed 2026-10-17)
7. National Cancer Institute: “Docetaxel” (link, accessed 2026-10-17)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.